BioCentury
ARTICLE | Finance

From Actos to act two

Why blood-brain penetration data convinced Ysios to lead Minoryx's series A

October 19, 2015 7:00 AM UTC

The improved properties of Minoryx Therapeutics S.L.'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round.

Minoryx is developing PPAR gamma agonists to treat X-linked adrenoleukodystrophy. The Orphan disease is characterized by accumulation of fatty acids in the adrenal cortex and CNS that results in adrenal insufficiency and progressive motor function deficits...